Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Sanofi (SNY) to EUR 90 from EUR 100 and keeps a Hold rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi’s Tolebrutinib Study: A Step Forward in Multiple Sclerosis Treatment
- Sanofi’s SAR443579 Study Terminated: Implications for Investors
- Sanofi’s New Study on Teplizumab: A Potential Game-Changer for Type 1 Diabetes in Japan
- Sanofi’s New Study on Lunsekimig: A Potential Game-Changer for Asthma Treatment
- Sanofi’s Teplizumab Study: A Potential Game-Changer for Type 1 Diabetes Treatment